| Faheem Hasnain |
Faheem Hasnain is the founder and currently holds the position of Chairman, President & Chief Executive Officer at Gossamer Bio, Inc., which was founded in 2015. He is also currently serving as Chairman at SENTÉ, Inc. (California), Aspen Neuroscience, Inc., SENTÉ Labs, Sling Therapeutics, Inc., and Vertex Ventures HC. Additionally, he is the Lead Independent Director at Kura Oncology, Inc. and a Member-Overseers Board at The Scripps Research Institute. In his former positions, Mr. Hasnain served as President, Chief Executive Officer & Director at Abbott Biotherapeutics Corp. from 2008 to 2010, President, Chief Executive Officer & Director at Receptos LLC from 2010 to 2015, President, Chief Executive Officer & Director at PDL BioPharma, Inc. in 2008, Chairman at Ambit Biosciences Corp. from 2010 to 2014, Chairman at Tocagen, Inc. from 2014 to 2020, Chairman at Mirati Therapeutics, Inc. from 2019 to 2024, Chairman at Vital Therapies, Inc. from 2017 to 2019, Chairman at Panacea Acquisition Corp. from 2020 to 2021, Chairman at Tercica, Inc. in 2008, Independent Director at Somaxon Pharmaceuticals, Inc. from 2010 to 2013, Independent Director at Aragon Pharmaceuticals, Inc. from 2012 to 2013, Director at Seragon Pharmaceuticals, Inc. from 2013 to 2015, Director at Pernix Sleep, Inc., President-Oncology Therapeutics Network at Bristol Myers Squibb Co. from 2002 to 2004, Executive Vice President-Oncology at Biogen, Inc. from 2004 to 2008, Vice President-Global eBusiness at GSK Plc from 1988 to 2002, EVP-Oncology & Rheumatology Strategic Business at Biogen Idec, Inc. (North Carolina) from 2004 to 2008, and President at Oncology Therapeutics Network Corp. from 2002 to 2004. Mr. Hasnain obtained his undergraduate degree from the University of Windsor in 1983. |
| Rainer Zimmermann |
Rainer Zimmermann is currently working as the Vice President-Medical Affairs at Gossamer Bio, Inc. He holds a doctorate degree from RWTH Aachen University. |
| Richard Aranda |
Richard Aranda is currently the Chief Medical Officer at Gossamer Bio, Inc. He previously worked as the Vice President-Clinical Development at Receptos LLC from 2015 to 2018, the Vice President-Medical Science & Inflammation at Novo-Nordisk Biochem, Inc. from 2011 to 2015, and as a Principal at Bristol Myers Squibb Co. from 2001 to 2011. He obtained his undergraduate degree from the University of California, Santa Cruz and his doctorate degree from Stanford School of Medicine. |
| Bryan Giraudo |
Bryan Giraudo is an Independent Director at Valerio Therapeutics SA since 2021. He is also an Independent Director at Protagonist Therapeutics, Inc. since 2018. Additionally, Mr. Giraudo serves as the Chief Operating & Financial Officer at Gossamer Bio, Inc. since 2021. Previously, Mr. Giraudo worked as a Senior Managing Director at Leerink Partners LLC from 2009 to 2018. Prior to that, he was a Managing Director at Merrill Lynch & Co., Inc. from 1997 to 2009. He also held a position as a Managing Director at Pierce Fenner & Smith, Inc.Mr. Giraudo completed his undergraduate degree from Georgetown University in 1997. |
| Christian Waage |
Mr. Christian Waage is an EVP-Technical Operations & Administration at Gossamer Bio, Inc. and an Independent Director at Heron Therapeutics, Inc. He is on the Board of Directors at Heron Therapeutics, Inc. Mr. Waage was previously employed as a Senior Vice President & General Counsel by Receptos LLC, a Secretary, Vice President & General Counsel by Websense, Inc., a Secretary, General Counsel & Vice President by Websense LLC, a Secretary, Vice President & General Counsel by Ardea Biosciences, Inc., a Partner by DLA Piper LLP (United States), a Managing Director by Celgene Corp., and a Principal by DLA Piper Rudnick Gray Cary US LLP. He received his undergraduate degree from the University of California San Diego and a graduate degree from the University of San Diego School of Law. |
| Bob Smith |
Bob Smith is currently the Chief Commercial Officer at Gossamer Bio, Inc. Prior to his current position, he served as the President at Ltm Pharma Consulting, Inc. from 2019 to 2023. Bob also held the role of Senior Vice President-Sales at Janssen Global Services LLC from 2012 to 2018, as well as at Actelion Ltd. from 2012 to 2018. He obtained his undergraduate degree from Texas A&M University. |
| Thomas O. Daniel |
Thomas O. Daniel's current job(s) include Chairman-Overseers Board at The Scripps Research Institute, Chairman at Locanabio, Inc., Chairman-Managers Board at Life Science Cares San Diego LLC, Chairman at Gate Therapeutics, Chairman at Trotana, Inc., Director at FerruMax Pharmaceuticals, Inc., Director at Lupus Research Alliance, Inc., Independent Director at Gossamer Bio, Inc., Director at Aspen Neuroscience, Inc., Director at Mozart Therapeutics, Inc., and Trustee at The Reed Institute. Dr. Daniel's former job(s) include Chairman-Research Division at Celgene Corp., Independent Director at Zafgen, Inc., Director at Abide Therapeutics, Inc., Director at PharmAkea, Inc., Chief Scientific Officer & Director at Ambrx, Inc., Director at Alliance for Lupus Research, Director at Pharmaceutical Research & Manufacturers of America, Director at Epizyme, Inc., Director at ImmusanT, Inc., Independent Director at Juno Therapeutics, Inc., Executive Director at Catalyst Advisors LP, Independent Director at Magenta Therapeutics, Inc., Independent Director at Vir Biotechnology, Inc., Director at Vanderbilt Vascular Biology Center, Director at Sana Biotechnology, Inc., Independent Director at Larimar Therapeutics, Inc., Director at Vividion Therapeutics, Inc., Vice President-Research at Amgen, Inc., Senior Vice President-Discovery Research at Immunex Corp., and Venture Partner at ARCH Venture Partners LLC. Dr. Daniel's education history includes an undergraduate degree from Southern Methodist University, a doctorate degree from The University of Texas at Austin, and a doctorate degree from The University of Texas Southwestern Medical Center. |
| Steven D. Nathan |
Steven D. Nathan is currently the Director-Advance Lung Disease Program at Inova Health Care Services since 1996 and an Independent Director at Gossamer Bio, Inc. since 2024. He is also a Member of the International Society for Heart & Lung Transplantation, the American Thoracic Society, Inc., and the American College of Chest Physicians. Dr. Nathan completed his undergraduate degree at the University of the Witwatersrand. |
| Renée D. Galá |
Renée D. Galá is currently serving as the Independent Director at Gossamer Bio, Inc. since 2018. Additionally, Ms. Galá holds the position of President & Chief Operating Officer at Jazz Pharmaceuticals Plc since 2020 and at Jazz Pharmaceuticals Ireland Ltd. since 2020. Previously, Ms. Galá has served as the Independent Director at Corcept Therapeutics, Inc. from 2016 to 2019. Ms. Galá also held the position of Non-Executive Director at Gyroscope Therapeutics Holdings Plc from 2020 to 2022 and Director at Gyroscope Therapeutics Ltd. from 2020 to 2022. Furthermore, Ms. Galá worked as the Vice President-Finance at Innoviva, Inc. from 2013 to 2014 and as a Principal at Eli Lilly & Company (Ireland) Ltd. from 2001 to 2006. Ms. Galá served as the Chief Financial Officer, Treasurer & Senior VP at Theravance Biopharma, Inc. from 2014 to 2019 and as the Chief Financial Officer at GRAIL LLC in 2019. Lastly, Ms. Galá held the position of Chief Financial Officer & Executive Vice President at Jazz Pharmaceuticals, Inc. from 2020 to 2024. Ms. Galá completed an undergraduate degree at Vanderbilt University and obtained an MBA from Columbia Business School. |
| Sandra Milligan |
Dr. Sandra Milligan, MD, is a President at Aspira Women's Health, Inc. and an Independent Director at Gossamer Bio, Inc. She is on the Board of Directors at Spyre Therapeutics, Inc. and Gossamer Bio, Inc. Dr. Milligan was previously employed as a Head-Research & Development by Organon & Co., a Head-Global Regulatory Affairs & Clinical Safety by Merck & Co., Inc., a Vice President-Product Development Regulatory by Genentech, Inc., a Vice President-Product Development Regulatory by Amgen, Inc., and a Principal by The United States Army Medical Service Corps. She also served on the board at Drug Information Association. She received her undergraduate degree from the University of California, Irvine, a graduate degree from Georgetown University Law Center and a doctorate degree from George Washington University School of Medicine & Health. |
| Russell J. Cox |
Russell J. Cox is currently the President & Chief Executive Officer at Epirium Bio, Inc., the Director at Vascular Cures, and an Independent Director at Gossamer Bio, Inc. Previously, he served as the Chief Executive Officer & Director at Vital Therapies, Inc., the Co-Chief Executive Officer & Director at Immunic, Inc., the Chairman at Spyre Therapeutics, Inc., and the Group Product Manager at Genentech, Inc. He also held positions as the Vice President-Marketing at Scios, Inc. and Tercica, Inc., the Chief Commercial Officer & EVP at Jazz Pharmaceuticals, Inc., and the Chief Commercial Officer & Senior Vice President at Ipsen, Inc. Additionally, he served as the Chief Operating Officer & Executive Vice President at Jazz Pharmaceuticals Plc. Mr. Cox obtained his undergraduate degree from Texas A&M University in 1985. |
| Skye Yayoi Drynan |
Skye Yayoi Drynan is the founder of House of Skye LTD, a company founded in 2016, where they currently hold the title of Chief Executive Officer & Creative Director. Ms. Drynan is also currently working as an Independent Director at Gossamer Bio, Inc. since 2024 and as an Analyst at Capital Research & Management Co. (International Investors) since 2008. Ms. Drynan previously worked as a Research Analyst at Lord, Abbett & Co. LLC in 2007, as an Analyst at Putnam LLC, Credit Suisse Asset Management LLC, and Capital Guardian Trust Co., as well as a Vice President at New Vernon Associates, Inc. Ms. Drynan also held the position of Principal at Whitehead Institute for Biomedical Research. Ms. Drynan completed their undergraduate degree at Wellesley College. |
| John D. Quisel |
John D. Quisel is currently serving as the President, Chief Executive Officer & Director at Disc Medicine Opco, Inc. and Disc Medicine, Inc. He is also an Independent Director at Gossamer Bio, Inc. Additionally, he serves as an Advisor at Atlas Venture Advisors, Inc. Previously, Dr. Quisel held positions as the Chief Executive Officer & Director at Gemini Therapeutics, Inc. He also served as the Secretary & Senior VP-Corporate Development at Acceleron Pharma, Inc. from 2006 to 2018. Prior to that, he worked as an Attorney at Foley Hoag LLP and Ropes & Gray LLP. Dr. Quisel completed his undergraduate studies at Harvard University in 1993. He then pursued his graduate degree at Stanford University in 1996. In 2000, he obtained a doctorate degree from the Massachusetts Institute of Technology. He later earned a graduate degree from Harvard Law School in 2004. He also attended Harvard College for his undergraduate studies. |
